Head-to-head evidence
fluticasone propionate/salmeterol vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone propionate/salmeterol
Developed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The trial randomized 908 participants to combination therapy, fluticasone propionate, or placebo under double-blind conditions. Its primary endpoint was change in daily evening peak expiratory flow after 12 weeks, a pulmonary-function surrogate, and the registry does not report whether this endpoint was met.
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone propionate/salmeterol's landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape